复方消化酶片联合埃索美拉唑治疗功能性消化不良腹胀上腹痛综合征临床研究
|
摘要
目的:探讨复方消化酶片联合埃索美拉唑肠溶胶囊治疗伴有腹胀上腹痛综合征(EPS)型功能性消化不良(FD)的临床效果。方法:选择EPS型FD患者157例,随机分为观察组(n=79)、对照组(n=78)。对照组予以埃索美拉唑肠溶胶囊治疗,观察组予以复方消化酶片联合埃索美拉唑肠溶胶囊治疗。观察2组治疗前及治疗1个疗程后胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)水平、胃窦收缩幅度、疗效及不良反应。结果:治疗后,观察组PGⅠ[(94.01±8.65) ng/mL]、PGⅡ[(5.98±1.77) ng/mL]水平分别低于对照组的[(124.98±10.02) ng/mL、(9.02±1.58) ng/mL](P<0.05),胃窦收缩幅度[(0.29±0.03)%]高于对照组[(0.25±0.02)%],总有效率(97.47%)高于对照组(83.33%)(P <0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:复方消化酶片联合埃索美拉唑肠溶胶囊治疗EPS型FD疗效显著,能有效改善消化功能,且不良反应少。
Objective:To investigate the clinical effect of compound digestive enzyme tablets combined with esomeprazole enteric-coated capsules in the treatment of functional dyspepsia(FD) with abdominal distension and upper abdominal pain syndrome(EPS).Methods:A total of 157 patients with EPS type FD were randomly divided into observation group(n=79) and control group(n=78).The control group was treated with esomeprazole enteric-coated capsules,and the observation group was treated with compound digestive enzyme tablets combined with esomeprazole enteric-coated capsules.PepsinogenⅠ(PGⅠ),pepsinogen Ⅱ(PGⅡ) levels,gastric sinus contraction amplitude,efficacy and adverse reactions were observed before and after 1 course of treatment.Results:After treatment,the levels of PGⅠ[(94.01±8.65) ng/mL]and PGⅡ[(5.98±1.77) ng/mL]in the observation group were lower than those in the control group [(124.98±10.02) ng/mL,(9.02±1.58) ng/mL](P<0.05),the amplitude of gastric antrum contraction [(0.29±0.03) %]was higher than that of the control group [(0.25± 0.02) %],the total effective rate(97.47%) was higher than that of the control group(83.33%)(P<0.05);the incidence of adverse reactions in the observation group was not significantly different from that in the control group(P>0.05).Conclusion:Compound digestive enzyme tablets combined with esomeprazole enteric-coated capsules have significant curative effect on EPS type FD,which can effectively improve gastric digestive function and less adverse reactions.
Objective:To investigate the clinical effect of compound digestive enzyme tablets combined with esomeprazole enteric-coated capsules in the treatment of functional dyspepsia(FD) with abdominal distension and upper abdominal pain syndrome(EPS).Methods:A total of 157 patients with EPS type FD were randomly divided into observation group(n=79) and control group(n=78).The control group was treated with esomeprazole enteric-coated capsules,and the observation group was treated with compound digestive enzyme tablets combined with esomeprazole enteric-coated capsules.PepsinogenⅠ(PGⅠ),pepsinogen Ⅱ(PGⅡ) levels,gastric sinus contraction amplitude,efficacy and adverse reactions were observed before and after 1 course of treatment.Results:After treatment,the levels of PGⅠ[(94.01±8.65) ng/mL]and PGⅡ[(5.98±1.77) ng/mL]in the observation group were lower than those in the control group [(124.98±10.02) ng/mL,(9.02±1.58) ng/mL](P<0.05),the amplitude of gastric antrum contraction [(0.29±0.03) %]was higher than that of the control group [(0.25± 0.02) %],the total effective rate(97.47%) was higher than that of the control group(83.33%)(P<0.05);the incidence of adverse reactions in the observation group was not significantly different from that in the control group(P>0.05).Conclusion:Compound digestive enzyme tablets combined with esomeprazole enteric-coated capsules have significant curative effect on EPS type FD,which can effectively improve gastric digestive function and less adverse reactions.
引文
[1]李慧,汤海涛,王修中,等.不同亚型功能性消化不良患者血清CRF水平及其与焦虑/抑郁的关系[J].临床消化病杂志,2016,28(6):333-337.
[2]苏青,涂蕾,贾小红,等.气滞胃痛颗粒治疗功能性消化不良患者随机、双盲、安慰剂对照临床研究[J].临床消化病杂志,2016,28(4):216-219.
[3]饶平,洪小枝.泮托拉唑钠肠溶片联合复方消化酶胶囊治疗30例功能性消化不良患者的疗效分析[J].当代医学,2018,24(19):64-66.
[4]郭新文,王隽,阿不力克·木克里木,等.疏肝解郁胶囊联合文拉法辛治疗抑郁症合并功能性消化不良的临床疗效和安全性研究[J].中国现代医学杂志,2016,26(20):133-136.
[5]安万杰,苏高建,胡静.枸橼酸莫沙必利分散片联合氟哌噻吨美利曲辛片治疗功能性消化不良的临床疗效观察[J].实用临床医药杂志,2017,21(21):189-190.
[6]郭芃利,古赛.质子泵抑制剂联合复方消化酶片治疗伴腹胀的上腹痛综合征型功能性消化不良的临床观察[J].中国药房,2016,27(12):1608-1610.
[7]赖人旭,任江南,苟新敏,等.铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究[J].中国临床药理学杂志,2017,33(19):1868-1870.
[8]贺东黎,张旖旎,曲青山.埃索美拉唑肠溶片联合理中丸治疗胃溃疡的临床研究[J].中国临床药理学杂志,2017,33(10):870-872.
[9]颜耀东,温泉,董宏鸿,等.复方消化酶片治疗消化不良症状的临床疗效和安全性[J].中国临床药学杂志,2016,25(6):357-360.
[10]王本贤.复方消化酶胶囊联合泮托拉唑治疗功能性消化不良的疗效观察[J].现代药物与临床,2017,32(7):1281-1284.
[11]吴咏冬,胡善联,何江江,等.复方消化酶片治疗消化不良的有效性及药品经济学研究[J].中国医刊,2015,50(11):58-61.
[12]杨艳,王峻峰.质子泵抑制剂联合复方消化酶片治疗伴腹胀的上腹痛综合征型功能性消化不良的临床观察[J].中国医师杂志,2018,20(4):577.
[13]黄颖杰,郑新梅.柴胡疏肝散对功能性消化不良肝气郁结证患者胃动力及胃肠激素的影响[J].现代中西医结合杂志,2016,25(13):1408-1410.
[14]陈欧,羊建,邱雄,等.胃黏膜血清检测技术及Hp-IgG抗体在萎缩性胃炎、胃癌和功能性消化不良中的诊断价值[J].中华消化内镜杂志,2016,33(7):471-472.
[2]苏青,涂蕾,贾小红,等.气滞胃痛颗粒治疗功能性消化不良患者随机、双盲、安慰剂对照临床研究[J].临床消化病杂志,2016,28(4):216-219.
[3]饶平,洪小枝.泮托拉唑钠肠溶片联合复方消化酶胶囊治疗30例功能性消化不良患者的疗效分析[J].当代医学,2018,24(19):64-66.
[4]郭新文,王隽,阿不力克·木克里木,等.疏肝解郁胶囊联合文拉法辛治疗抑郁症合并功能性消化不良的临床疗效和安全性研究[J].中国现代医学杂志,2016,26(20):133-136.
[5]安万杰,苏高建,胡静.枸橼酸莫沙必利分散片联合氟哌噻吨美利曲辛片治疗功能性消化不良的临床疗效观察[J].实用临床医药杂志,2017,21(21):189-190.
[6]郭芃利,古赛.质子泵抑制剂联合复方消化酶片治疗伴腹胀的上腹痛综合征型功能性消化不良的临床观察[J].中国药房,2016,27(12):1608-1610.
[7]赖人旭,任江南,苟新敏,等.铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究[J].中国临床药理学杂志,2017,33(19):1868-1870.
[8]贺东黎,张旖旎,曲青山.埃索美拉唑肠溶片联合理中丸治疗胃溃疡的临床研究[J].中国临床药理学杂志,2017,33(10):870-872.
[9]颜耀东,温泉,董宏鸿,等.复方消化酶片治疗消化不良症状的临床疗效和安全性[J].中国临床药学杂志,2016,25(6):357-360.
[10]王本贤.复方消化酶胶囊联合泮托拉唑治疗功能性消化不良的疗效观察[J].现代药物与临床,2017,32(7):1281-1284.
[11]吴咏冬,胡善联,何江江,等.复方消化酶片治疗消化不良的有效性及药品经济学研究[J].中国医刊,2015,50(11):58-61.
[12]杨艳,王峻峰.质子泵抑制剂联合复方消化酶片治疗伴腹胀的上腹痛综合征型功能性消化不良的临床观察[J].中国医师杂志,2018,20(4):577.
[13]黄颖杰,郑新梅.柴胡疏肝散对功能性消化不良肝气郁结证患者胃动力及胃肠激素的影响[J].现代中西医结合杂志,2016,25(13):1408-1410.
[14]陈欧,羊建,邱雄,等.胃黏膜血清检测技术及Hp-IgG抗体在萎缩性胃炎、胃癌和功能性消化不良中的诊断价值[J].中华消化内镜杂志,2016,33(7):471-472.